1
/
of
1
NK Induction and Expansion Kit
NK Induction and Expansion Kit
Cellarom Store
Request for QuoteNK induction and expansion kit provides high purity of CD3-/CD56+ NK cells with high cytotoxic ability from both peripheral blood mononuclear cells (PBMCs) and cord blood mononuclear cells (CBMCs).
- No feeder cells required, safe for clinical application.
- IL-2 is required for NK induction and expansion.
- Serum (or EliteMu) is essential
- No additional cytokines are needed
- RUO
- GMP
Application
Application
NK cells (natural killer cells) are a type of cytotoxic lymphocyte critical to the innate immune system. The role of NK cells in both the innate and adaptive immune responses is becoming increasingly important in research, e.g. using NK cell activity as a potential cancer therapy. Simple culture process without feeder cells and pre-coating, EliteCell NK kit enables to obtain high purity of CD3-/CD56+ NK cells with high cytotoxic ability from both peripheral blood mononuclear cells (PBMCs) and cord blood mononuclear cells (CBMCs).
Cell Type
Cell Type
Storage
Storage
- 2-8 C protect from light for NK media
- -20C for supplement
Specification
Specification
- Suitable for MNC (mononuclear cells) from whole blood and cord blood source.
- 70%-90% NK cells (CD3-CD56+) at Day 14.
- 1.0- 2.0 x10^9 total cells (per L) at Day 14.
- 80%-100% cytotoxicity at E/T ratio 5:1, better efficacy.
Share

Request for Quote
Contact us for quote and additional information
Scale up your NK development work from discovery to clinical trials

Empowering Cell Therapy Organizations to Innovate
Cellarom was born from a desire to bridge the gap between research and development, pilot production and commercialization. We recognized the challenge of balancing scientifically acceptable product performance with the need to reduce manufacturing costs to produce cost-effective therapies.
At Cellarom, we are dedicated to:
- Bridging Product Development and Commercialization in Cell Therapy
- Cost-Effective and High-Quality Cell Therapy raw materials and solutions
- Capability for Scaling Up Cell Therapy Production